SoftBank’s AI investments face increasing risks, especially in OpenAI and Stargate. Find out why SFTBF stock could be overvalued amid mixed earnings results.
Former US Treasury Secretary Steven Mnuchin and SoftBank Group Corp.’s Vision Fund are discussing a deal to salvage Cybereason Inc., a onetime Silicon Valley unicorn that has lost most of its value amid boardroom turmoil.
SoftBank Group Corp. Chief Executive Officer Masayoshi Son acknowledged that his company’s partnership with Mohammed Bin Salman’s Public Investment Fund has failed to fully deliver for the Saudi prince.
Nissan Motor Co.’s credit-default swaps widened to the most among Japanese companies, overtaking both Rakuten Group Inc. and SoftBank Group Corp. after its consolidation talks with Honda Motor Co. were terminated.
Key Takeaways Masayoshi Son, founder and CEO of Japanese multinational investment company SoftBank Group,has an estimated net worth of $17 billion, according to Bloomberg. Son has a 29% stake in Softbank.
Investigators hired by the board of eFishery Pte. have determined the Indonesian startup is in far worse shape than they previously thought, and that investors are likely to get back less than 10 cents for every dollar they invested,
OpenAI is forecasting a major shift in the next five years around who it gets most of its computing power from, The Information reported on Friday. By
At the FII PRIORITY Summit 2025 in Miami, Florida, SoftBank founder Masayoshi Son made his first public response to doubts about the US$500 billion Stargate initiative. Backed by SoftBank, OpenAI, and Oracle,
OpenAI is reportedly planning to shift its compute needs away from Microsoft and instead rely on capacity provided by its Stargate partner SoftBank.
Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies in the space with this
New forecasts from OpenAI are showing the beginning of a dramatic shift in its alliances from its largest shareholder, Microsoft (MSFT), to
SoftBank disclosed a 20.45M share position in PacBio (PACB) and 14.67M share position in Recursion Pharmaceuticals (RXRX) in a regulatory
Some results have been hidden because they may be inaccessible to you
Show inaccessible results